financetom
Technology
financetom
/
Technology
/
Investigating Lam Research's Standing In Semiconductors & Semiconductor Equipment Industry Compared To Competitors
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Investigating Lam Research's Standing In Semiconductors & Semiconductor Equipment Industry Compared To Competitors
Aug 15, 2024 8:31 AM

In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we will conduct a comprehensive industry comparison, evaluating Lam Research ( LRCX ) against its key competitors in the Semiconductors & Semiconductor Equipment industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.

Lam Research Background

Lam Research ( LRCX ) is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segments of deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear cut second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.

Company P/E P/B P/S ROE EBITDA (in billions) Gross Profit (in billions) Revenue Growth
Lam Research Corp ( LRCX ) 29.15 12.91 7.49 12.32% $1.21 $1.84 2.05%
ASML Holding NV 46.96 21.50 12.45 11.07% $2.06 $3.21 -9.55%
Applied Materials Inc 23.18 9.17 6.39 9.67% $2.15 $3.15 0.24%
KLA Corp 39.15 31.68 11.02 25.88% $1.13 $1.56 9.07%
Teradyne Inc 41.20 7.48 7.55 7.04% $0.25 $0.43 6.64%
Entegris Inc 89 4.64 4.97 1.95% $0.22 $0.38 -9.81%
Enphase Energy Inc 119.52 17.02 10.83 1.2% $0.03 $0.14 -57.33%
Onto Innovation Inc 59.44 5.37 11 2.93% $0.07 $0.13 27.1%
Amkor Technology Inc 20.94 1.94 1.23 1.66% $0.25 $0.21 0.24%
MKS Instruments Inc 759.40 3.43 2.14 0.99% $0.19 $0.42 -11.57%
FormFactor Inc 30.38 3.82 5.22 2.07% $0.02 $0.09 26.65%
Axcelis Technologies Inc 15.18 3.85 3.27 5.54% $0.06 $0.11 -6.37%
Veeco Instruments Inc 23.58 2.86 3.02 2.2% $0.03 $0.08 8.81%
Photronics Inc 10.54 1.39 1.59 3.52% $0.1 $0.08 -5.37%
ACM Research Inc 15.74 1.48 1.86 2.97% $0.04 $0.1 40.05%
Aehr Test Systems 12.11 3.59 6.06 24.09% $0.0 $0.01 -25.46%
inTest Corp 18.03 0.84 0.66 0.23% $0.0 $0.01 4.4%
Average 82.77 7.5 5.58 6.44% $0.41 $0.63 -0.14%

table {

width: 100%;

border-collapse: collapse;

font-family: Arial, sans-serif;

font-size: 14px;

}

th, td {

padding: 8px;

text-align: left;

}

th {

background-color: #293a5a;

color: #fff;

text-align: left;

}

tr:nth-child(even) {

background-color: #f2f4f8;

}

tr:hover {

background-color: #e1e4ea;

}

td:nth-child(3), td:nth-child(5) {

text-align: left;

}

.dividend-amount {

font-weight: bold;

color: #0d6efd;

}

.dividend-frequency {

font-size: 12px;

color: #6c757d;

}

By closely studying Lam Research ( LRCX ), we can observe the following trends:

With a Price to Earnings ratio of 29.15, which is 0.35x less than the industry average, the stock shows potential for growth at a reasonable price, making it an interesting consideration for market participants.

It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of 12.91 which exceeds the industry average by 1.72x.

The Price to Sales ratio of 7.49, which is 1.34x the industry average, suggests the stock could potentially be overvalued in relation to its sales performance compared to its peers.

With a Return on Equity (ROE) of 12.32% that is 5.88% above the industry average, it appears that the company exhibits efficient use of equity to generate profits.

With higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.21 Billion, which is 2.95x above the industry average, the company demonstrates stronger profitability and robust cash flow generation.

The gross profit of $1.84 Billion is 2.92x above that of its industry, highlighting stronger profitability and higher earnings from its core operations.

The company's revenue growth of 2.05% exceeds the industry average of -0.14%, indicating strong sales performance and market outperformance.

Debt To Equity Ratio

The debt-to-equity (D/E) ratio provides insights into the proportion of debt a company has in relation to its equity and asset value.

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

By considering the Debt-to-Equity ratio, Lam Research ( LRCX ) can be compared to its top 4 peers, leading to the following observations:

Lam Research ( LRCX ) exhibits a stronger financial position compared to its top 4 peers in the sector, as indicated by its lower debt-to-equity ratio of 0.58.

This suggests that the company has a more favorable balance between debt and equity, which can be seen as a positive aspect for investors.

Key Takeaways

For Lam Research ( LRCX ), the PE ratio is low compared to peers, indicating potential undervaluation. The PB and PS ratios are high, suggesting overvaluation relative to industry standards. On the other hand, Lam Research ( LRCX ) shows high ROE, EBITDA, gross profit, and revenue growth, reflecting strong financial performance and growth prospects within the Semiconductors & Semiconductor Equipment sector.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Expert Outlook: Five9 Through The Eyes Of 16 Analysts
Expert Outlook: Five9 Through The Eyes Of 16 Analysts
Aug 23, 2024
Ratings for Five9 ( FIVN ) were provided by 16 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings...
Analyst Ratings For Iris Energy
Analyst Ratings For Iris Energy
Aug 23, 2024
Across the recent three months, 9 analysts have shared their insights on Iris Energy ( IREN ) , expressing a variety of opinions spanning from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat...
A Glimpse Into The Expert Outlook On Okta Through 10 Analysts
A Glimpse Into The Expert Outlook On Okta Through 10 Analysts
Aug 23, 2024
Okta ( OKTA ) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 3...
So-Young International Q2: Revenue Declines, Lower Mobile Users, Disappointing Outlook & More
So-Young International Q2: Revenue Declines, Lower Mobile Users, Disappointing Outlook & More
Aug 23, 2024
So-Young International Inc ( SY ) reported fiscal second-quarter revenue of $56.1 million, beating the analyst consensus estimate of $54.3 million. Revenues declined 1.1% year-over-year.  The China-based consumption healthcare services provider registered an adjusted EPADS of $0.03, in line with the analyst consensus estimate.  Information services and other revenues were $38.4 million (-6.6% Y/Y), primarily due to decreased medical service providers subscribing to information services on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved